GlassScriptPhysician profile
Douglas Stamm
NPI 1942730957
$1,011.80
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $872 · 2020: $140.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $199.25 | 2019-2020 | |
| Daiichi Sankyo INC. | $180.49 | 2019 | |
| Pfizer INC. | $109.00 | 2019 | |
| Allergan, INC. | $100.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $98.07 | 2019 | |
| Gilead Sciences, INC. | $91.66 | 2019 | |
| Novo Nordisk INC | $69.09 | 2019 | |
| Lilly USA, LLC | $39.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.19 | 2020 | |
| Shire North American Group INC | $33.13 | 2019 | |
| Amarin Pharma, INC. | $25.63 | 2020 | |
| Abbvie INC. | $15.73 | 2019 | |
| Sanofi Pasteur INC. | $13.52 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Stamm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.